CD8+ T Lymphocytes in Hypopigmented Mycosis Fungoides: Malignant Cells or Reactive Clone?
- PMID: 36116507
- PMCID: PMC11186597
- DOI: 10.1016/j.jid.2022.08.047
CD8+ T Lymphocytes in Hypopigmented Mycosis Fungoides: Malignant Cells or Reactive Clone?
Conflict of interest statement
CONFLICT OF INTEREST
OEA has received research funding/grant support from Actelion, Adaptive Biotechnology, Trillium Therapeutics, Pfizer, Kyowa Kirin, and Malinkrodt; serves as a principal investigator on current clinical trials: Trillium, Eisai, Affimed, Innate Pharma, Tellomak, and Corvus; OEA is a consultant for Castle Biomarkers, SkinJet, Bioniz, Kyowa-Hakka-Kirin, and Allmiral; and OEA is a speaker for Kyowa Kirin and Helsin. The remaining authors state no conflict of interest.
Figures
References
-
- Amorim GM, Niemeyer-Corbellini JP, Quintella DC, Cuzzi T, Ramos-E-Silva M. Hypopigmented mycosis fungoides: a 20-case retrospective series. Int J Dermatol 2018;57:306–12. - PubMed
-
- El-Shabrawi-Caelen L, Cerroni L, Medeiros LJ, McCalmont TH. Hypopigmented mycosis fungoides: frequent expression of a CD8 T-cell phenotype. Am J Surg Pathol 2002;26:450–7. - PubMed
-
- Jonak C, Alkon N, Rindler K, Rojahn TB, Shaw LE, Porkert S, et al. Single-cell RNA sequencing profiling in a patient with discordant primary cutaneous B-cell and T-cell lymphoma reveals micromilieu-driven immune skewing. Br J Dermatol 2021;185:1013–25. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
